nabiximols

Nabiximols and other cannabis-based preparations sometimes used with multiple sclerosis (MS) appear to work well for controlling spasticity, a common disease symptom that occurs when muscles stiffen or tighten, a meta-analysis of findings in published studies reported. Larger studies into cannabis-based treatments of spasticity for these patients…

Nabiximols, a cannabis-based oral spray sold as Sativex, was reported to considerably ease spasticity — unusual muscle tightness or stiffness — in about two-thirds of the multiple sclerosis (MS) patients using it for three months in a real-world study in Germany. For most patients, the treatment also…

Nabiximols, the cannabis-based oral spray sold as Sativex, is available for reimbursement as an add-on therapy for moderate to severe spasticity in adults with multiple sclerosis (MS) in Ireland who failed to respond as intended to other spasticity medications. Marked by muscle stiffness and involuntary spasms or twitches,…

Treatment with the cannabis oral spray nabiximols helped to relieve spasticity — increased muscle stiffness and spasms common in people with multiple sclerosis (MS) — among participants in two MS clinical trials, according to the results of a new analysis. “In this analysis, nabiximols was shown to significantly…

Real-world use of nabiximols, an oral spray cannabinoid treatment, was associated with a self-reported easing of spasticity and related symptoms for people with multiple sclerosis (MS), according to a recent study in Austria. Most patients (87.5%) said they were at least partly satisfied with the therapy — available…

Four weeks of treatment with nabiximols — an oral spray containing compounds found in the cannabis plant — significantly reduced spasticity and generally improved arm and hand function in multiple sclerosis (MS) patients with moderate-to-severe spasticity, according to a small pilot study in Italy. Notably, after nabiximols, patients showed…

This news seems disappointing: A Phase 3 clinical trial of nabiximols — which is available under the brand name Sativex in several countries, including Canada and most of Europe — has failed to meet its primary goal of reducing leg spasticity in people with multiple sclerosis (MS). Nabiximols…

An assistive device made it significantly easier and more comfortable for multiple sclerosis (MS) patients with arm and hand mobility problems to self-administer nabiximols — an oral spray containing compounds found in the cannabis plant — a study found. Trained nurses involved in the study agreed with its…

The Phase 3 RELEASE MSS1 clinical trial testing nabiximols oral spray failed to meet its primary goal of easing leg spasticity in patients with multiple sclerosis (MS), according to Jazz Pharmaceuticals, the company currently developing the nabiximols clinical program. Enrolling 68 MS patients,…

Stem Cell Transplant Gaining Ground as MS Therapy Option This comprehensive look at stem cell transplants by Multiple Sclerosis News Today writer Hawken Miller is one of the best overviews of the possible benefits and dangers and the current status of autologous hematopoietic stem cell transplantation (aHSCT) that…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Sativex…

Trial Will Test Ocrevus on Arm, Hand Function in PPMS A lot of the focus in MS treatment and clinical trials is placed on walking ability. It seems to me that only recently has attention been paid to above-the-waist disabilities. I know that many people with MS have problems…

Sativex (nabiximols), a cannabis-based oral spray approved in the U.K. to ease spasticity — or muscle stiffness and spasms — in adults with multiple sclerosis (MS), remains unavailable to many patients there, according to a report by the MS Society UK. Sativex is the only licensed…

Trial Will Test Mavenclad for Advanced Progressive MS I often think that researchers have forgotten about people whose MS has progressed to an advanced stage. But MS patients who have moved into a wheelchair deserve treatment with a disease-modifying therapy as much as those who are just beginning their…

Jazz Pharmaceuticals is planning to open a third Phase 3 clinical trial of Sativex (nabiximols), an oral spray that contains cannabis extracts, as an add-on treatment for people with multiple sclerosis (MS) and spasticity, the company announced. Set to start this year, the RELEASE MSS5…

Sativex (nabiximols), an oral spray that contains cannabis extracts, was found effective as an add-on therapy for easing spasticity in adult multiple sclerosis (MS) patients who failed to respond to other anti-spastic treatments, a real-world study from Belgium reports. Overall, about 74% patients reported easing of spasticity — muscle stiffness or…

GW Pharmaceuticals is planning to continue recruiting patients into two pivotal Phase 3 clinical trials of Sativex (nabiximols), an oral spray that contains cannabis extracts and is being investigated as a potential add-on therapy for people with multiple sclerosis (MS) and spasticity. The company also is…

Phase 3 Trial of Sativex, Cannabis Extract Treatment for MS Spasticity, Opens in US This is a major step toward making a clinically tested, cannabis-based medication available in the U.S. I’ve always thought that medications containing a THC/CBD combination are useful to lessen some MS symptoms, but the lack…

A Phase 3 trial is underway in the U.S. to assess the safety and efficacy of Sativex (nabiximols), an oral spray that contains cannabis extracts, in treating spasticity — muscle stiffness or spasms — associated with multiple sclerosis (MS). Sativex, by…